特一药业(002728) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥164,611,744.46, a decrease of 45.88% compared to ¥304,157,421.18 in the same period last year[4] - Net profit attributable to shareholders was ¥9,154,620.96, down 91.32% from ¥105,470,920.94 year-on-year[4] - Basic earnings per share decreased to ¥0.03, down 90.91% from ¥0.46 in the same period last year[4] - Total operating revenue for Q1 2024 was CNY 164.61 million, a decrease of 46% compared to CNY 304.16 million in the same period last year[18] - Net profit for Q1 2024 was CNY 9.15 million, a decline of 91% compared to CNY 105.47 million in Q1 2023[19] - Earnings per share for Q1 2024 were CNY 0.03, down from CNY 0.33 in the previous year[20] Cash Flow - The net cash flow from operating activities was -¥39,376,492.11, representing a decline of 246.31% compared to ¥26,912,422.14 in the previous year[4] - Cash inflow from operating activities was CNY 167.28 million, a decrease of 29% from CNY 236.04 million in Q1 2023[21] - The net cash flow from operating activities was -39,376,492.11, compared to 26,912,422.14 in the previous year, indicating a significant decline[22] - The total cash outflow from investing activities was 66,834,461.53, up from 19,235,255.51 in the same period last year, resulting in a net cash flow from investing activities of -46,812,491.92[22] - Cash inflow from financing activities totaled 292,915,169.80, a substantial increase from 63,918,749.00 in the previous year[22] - The net cash flow from financing activities was -78,472,431.97, compared to -46,456,328.50 in the same period last year, reflecting increased cash outflows[22] - The ending balance of cash and cash equivalents was 382,154,235.62, down from 500,451,222.46 at the end of the previous year[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,469,349,204.84, a decrease of 1.19% from ¥2,498,981,899.98 at the end of the previous year[4] - Total current assets decreased from 1,105,152,948.38 to 1,055,271,427.23, a reduction of approximately 4.5%[15] - Cash and cash equivalents decreased from 647,247,165.22 to 562,585,749.22, a decline of about 13.1%[14] - Accounts receivable decreased from 97,807,658.06 to 80,049,776.38, a drop of approximately 18.2%[15] - Inventory increased from 271,831,790.86 to 295,488,911.37, an increase of about 8.7%[15] - Total liabilities decreased to CNY 448.94 million from CNY 501.95 million in the previous year[19] - The total equity attributable to shareholders increased to CNY 2.02 billion from CNY 2.01 billion year-over-year[19] Shareholder Information - Total number of common shareholders at the end of the reporting period is 72,743[10] - The largest shareholder, Xu Danqing, holds 27.41% of shares, totaling 99,981,000 shares[10] Expenses - The gross profit margin for the period was significantly impacted by a decline in sales of high-margin traditional Chinese medicine products[8] - The company reported a decrease in sales revenue primarily due to a drop in the sales of traditional Chinese medicine products[7] - The company has seen a significant reduction in financial expenses, down 151.80%, due to decreased financing costs and increased interest income[7] - Research and development expenses for Q1 2024 were CNY 11.10 million, an increase of 9% compared to CNY 10.18 million in the same period last year[19] - Sales expenses for Q1 2024 were CNY 36.07 million, slightly up from CNY 35.53 million year-over-year[19] Government Support - The company received government subsidies amounting to ¥370,029.31, which are expected to have a continuous impact on its profits[5] Other Information - The company has not reported any significant changes in the top 10 shareholders' participation in margin trading[11] - The company has not undergone an audit for the first quarter report[24]